Amyotrophic Lateral Sclerosis: all 1,000 studies

Page 6 of 10. Open to participants first (284), then studies with results posted, then the rest; newest registration first within each.

• Psychological Management by Meditation of Full COnscience in Virtual REality of People With Amyotrophic Lateral Sclerosis: Effects on Cognition, Behavior, Quality of Life and Psychological Well-beingWithdrawnNCT05409508Not applicable
• A Prospective Study to Evaluate the Correlation Between Oculometric Measurements and Clinical Endpoints in ALS PatientsCompletedNCT05407428
• Dazucorilant in Patients With Amyotrophic Lateral SclerosisActive, not recruitingNCT05407324Phase 2
• Study of Structural and Functional Brain Connectivity Changes in ALS (CoALS-II)CompletedNCT05404867Not applicable
• A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALSCompletedNCT05357950Phase 2
• Surface EMG and Ultrasound in MNDCompletedNCT05314348Not applicable
• CNS10-NPC-GDNF Delivered to the Motor Cortex for ALSActive, not recruitingNCT05306457Phase 1
• An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALSActive, not recruitingNCT05299658Phase 2
• Telemonitoring in NIV MND (OptNIVent)Status unknownNCT05299372Not applicable
• Evaluation of the Early Use of the Pressure Relaxer in the Respiratory Impairment of Patients With Amyotrophic Lateral Sclerosis: Multicenter Randomized Controlled Study.WithdrawnNCT05297487Not applicable
• An Assistive Powered Wheelchair: Stage 2 TrialCompletedNCT05292690
• An Intermediate Size Expanded Access Protocol of AMX0035 for ALSApproved for marketingNCT05286372
• A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALSActive, not recruitingNCT05279755Phase 1
• Home-based Remote Digital Monitoring to Assess ALS Progression (Track ALS)CompletedNCT05276349
• Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)Active, not recruitingNCT05218668Phase 2
• Online Self-Compassion Course for pALS (Compassion pALS)CompletedNCT05202743
• Triumeq in Amyotrophic Lateral SclerosisTerminatedNCT05193994Phase 3
• A Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Extension StudyActive, not recruitingNCT05095571Not applicable
• Neurofilament Assay for the Diagnosis of ALSStatus unknownNCT05077696
• SWITCH II Early Feasibility Study: Implantable BCI to Control a Digital Device for People With ParalysisWithdrawnNCT05041114Not applicable
• COMMAND Early Feasibility Study: Implantable BCI to Control a Digital Device for People With ParalysisActive, not recruitingNCT05035823Not applicable
• Optimizing INITIation of Non-invasive Ventilation in ALS PatientsStatus unknownNCT05033951
• NF-κB Inhibition in Amyotrophic Lateral SclerosisStatus unknownNCT05031351Phase 2
• Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis TreatmentActive, not recruitingNCT05021536Phase 3
• Olfactory Deficits in Neurologic DiseaseCompletedNCT05019014
• A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral SclerosisCompletedNCT05006352Phase 1
• Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intrathecal Injection for ALSWithdrawnNCT05003921Phase 1
• EMERALD TRIAL Open Label Extension StudyStatus unknownNCT04997954Phase 4
• A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTDCompletedNCT04993755Phase 2
• Multimodal Brain Imaging StudyStatus unknownNCT04960540
• Application of Motor Unit Estimation Index in Amyotrophic Lateral Sclerosis and Related DiseasesStatus unknownNCT04956822
• Appetite and Related Factors in Patients With ALSStatus unknownNCT04953624
• Pleiotropy and Mechanism of Peripheral Nerve Related Genes in the Progression of Amyotrophic Lateral SclerosisStatus unknownNCT04953494
• Home Care Needs and Current Nursing Status of Patients With Amyotrophic Lateral SclerosisStatus unknownNCT04953481
• Ocular Surface Metabolo-lipidomics in Lateral Amyotrophic SclerosisCompletedNCT04953286Not applicable
• Low Dose IL-2 in the Treatment of Immune-associated ALS SyndromeStatus unknownNCT04952155Phase 2
• Sleep Disorders and the Onset and Progression of ALSStatus unknownNCT04952038
• Quantitative Analysis of Precise Brain Volume in Amyotrophic Lateral SclerosisCompletedNCT04952025
• The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji GranulesStatus unknownNCT04950933Phase 2/3
• Efficacy and Safety of Nitrazine in the Treatment of ALSStatus unknownNCT04950647Phase 2
• Investigation on Home Care Needs of ALS Patients and Their CaregiversCompletedNCT04950231
• A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral SclerosisTerminatedNCT04948645Phase 1
• Correlation Between Intestinal Microflora Metabolites and Amyotrophic Lateral SclerosisCompletedNCT04948346
• Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric DisordersCompletedNCT04939818
• Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)TerminatedNCT04931862Phase 1/2
• EEG and TMS-based Biomarkers of ALS, MS and FTDStatus unknownNCT04918251
• A Study of Monepantel in Individuals With Motor Neurone DiseaseCompletedNCT04894240Phase 1
• Remote Speech and Swallowing Assessment in ALSCompletedNCT04889898
• Inspiratory Muscle Training With Powerbreath Device in Patients With ALSCompletedNCT04889248Not applicable
• Anti-Cholinergic Receptors Antibodies, Autonomic Profile and Dysautonomia Symptoms in PAF, ALS and POTS (DISAUT-AB)CompletedNCT04875949Not applicable
• Phenotype, Genotype and Biomarkers 2Active, not recruitingNCT04875416
• Staging System in Amyotrophic Lateral SclerosisActive, not recruitingNCT04858555
• Clinical Trial on the Use of Cell Therapy in the Treatment of Patients With Amyotrophic Lateral SclerosisStatus unknownNCT04849065Phase 2
• Enoxacin for Amyotrophic Lateral Sclerosis (ALS)CompletedNCT04840823Phase 1/2
• Hyperkinetic Movements in Patients With Disease of Motor Neurons and Their Response to Treatment With NusinersenStatus unknownNCT04825119
• Repeated Mesenchymal Stem Cell Injections in ALSCompletedNCT04821479Phase 1/2
• Efficacy and Tolerability of Beta Hydroxybutyrate Ester in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT04820478Not applicable
• Frequency of SOD1 and C9orf72 Gene Mutations in French ALSCompletedNCT04819555
• Xavier Electromyographic Wheelchair Control for Limited Mobility PatientsCompletedNCT04800926Not applicable
• NuroSleeve Powered Brace & Stimulation System to Restore Arm FunctionActive, not recruitingNCT04798378Not applicable
• Patient's TeleMonitoring With Amyotrophic Lateral Sclerosis Treated by Non Invasive Ventilation at Home.CompletedNCT04797845Not applicable
• Targeting Metabolic Flexibility in Amyotrophic Lateral Sclerosis (ALS)CompletedNCT04788745Phase 2
• FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)Active, not recruitingNCT04768972Phase 3
• RT001 in Amyotrophic Lateral SclerosisCompletedNCT04762589Phase 2
• Study of [11C]CPPC to Assess the Safety and Tolerability in Patients With ALSTerminatedNCT04749433Phase 1
• Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALSCompletedNCT04745299Phase 3
• iPSC-based Drug Repurposing for ALS Medicine (iDReAM) StudyCompletedNCT04744532Phase 1/2
• AIM's Writing for Healing: A Workshop for Individuals Living With ParalysisCompletedNCT04721717
• Determining Feasibility and Acceptability of Sharing Video Recordings With Patients With ALS and CaregiversCompletedNCT04719403Not applicable
• Virtual Peer-to-peer Support Programme for Carers of MNDCompletedNCT04695210Not applicable
• New Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral SclerosisCompletedNCT04691011Not applicable
• Analysis of Capillary Retinal and Papillary Vascularization in Patients With Amyotrophic Lateral Sclerosis - CAPISLAStatus unknownNCT04686110Not applicable
• Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALSNo longer availableNCT04681118
• Impact of the Combined Treatment of Liposomed Polyphenols With G04CB02 on the ALS PatientsCompletedNCT04654689Phase 2
• The Evaluation of the Effect of Mesenchymal Stem Cells on the Immune System of Patients With ALSStatus unknownNCT04651855Phase 1/2
• Exploratory Evaluation of [11C]MPC6827CompletedNCT04575727Early Phase 1
• Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT04569435Phase 2
• The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS.Active, not recruitingNCT04562831Not applicable
• COVID-19 Amyotrophic Lateral Sclerosis (ALS) RegistryCompletedNCT04559009
• Open Label Study: Treatment of ALS Fatigue With PolyMVACompletedNCT04557410Phase 1
• Explore Neuroprotective Effect of Lipoic Acid in Amyotrophic Lateral SclerosisStatus unknownNCT04518540Not applicable
• A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT04516096Phase 2/3
• Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral SclerosisNo longer availableNCT04514952
• Evaluate PU-AD in Subjects With Amyotrophic Lateral SclerosisWithdrawnNCT04505358Phase 2
• Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation ToolkitCompletedNCT04468919Not applicable
• Fatigue in Patients With Amyotrophic Lateral SclerosisWithdrawnNCT04468191Not applicable
• Peripheral Neurofilament Levels and Amyotrophic Lateral SclerosisCompletedNCT04455542
• Treatment of Intravenous Infusion Plasma in Amyotrophic Lateral SclerosisCompletedNCT04454840Early Phase 1
• Venous Disease Thromboembolic and Amyotrophic Lateral SclerosisCompletedNCT04446325
• Italian Validation of the Beaumont Behavioural Inventory (BBI)CompletedNCT04440644
• Respiratory Complications in ALSCompletedNCT04430686
• A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS DiseaseTerminatedNCT04428775Phase 2
• Transcranial Static Magnetic Field Stimulation (tSMS) in Amyotrophic Lateral Sclerosis (ALS).Status unknownNCT04393467Not applicable
• The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALSStatus unknownNCT04391361Phase 2
• Development and Test of a Headset for BCI Until Obtaining an Efficient and Comfortable System That Can be Used in Daily Practice by ALS PeopleActive, not recruitingNCT04380649Not applicable
• Neurobiological and Immunological Mechanisms of Dyspnea in ALS (BIOPNEA)Status unknownNCT04332198Not applicable
• Registration Study of Amyotrophic Lateral Sclerosis (ALS) in Mainland ChinaStatus unknownNCT04328675
• Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)TerminatedNCT04326283Phase 1/2
• Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001CompletedNCT04313166Phase 2
• IC14 for ALS Patients Expanded AccessNo longer availableNCT04309604

← Amyotrophic Lateral Sclerosis overview